Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-02-14 4:00 pm Purchase |
2022-12-31 | 13G | KalVista Pharmaceuticals, Inc. KALV |
TANG CAPITAL PARTNERS LP | 3,196,446 9.400% |
1,796,446 (+128.32%) |
Filing History |
| 2023-02-14 4:00 pm Purchase |
2022-12-31 | 13G | Metacrine, Inc. MTCR |
TANG CAPITAL PARTNERS LP | 4,250,000 9.980% |
1,208,623 (+39.74%) |
Filing History |
| 2023-02-14 4:00 pm Purchase |
2022-12-31 | 13G | Pyxis Oncology, Inc. PYXS |
TANG CAPITAL PARTNERS LP | 3,470,700 9.900% |
1,489,274 (+75.16%) |
Filing History |
| 2023-02-14 4:00 pm Purchase |
2022-12-31 | 13G | Reviva Pharmaceuticals Holdings, Inc. RVPH |
TANG CAPITAL PARTNERS LP | 2,266,229 9.990% |
916,049 (+67.85%) |
Filing History |
| 2023-02-14 4:00 pm Sale |
2022-12-31 | 13G | Tarsus Pharmaceuticals, Inc. TARS |
TANG CAPITAL PARTNERS LP | 2,001,585 7.500% |
-90,168 (-4.31%) |
Filing History |
| 2023-02-14 4:00 pm Sale |
2022-12-31 | 13G | TCR2 Therapeutics Inc. TCRR |
TANG CAPITAL PARTNERS LP | 2,738,947 7.100% |
-61,053 (-2.18%) |
Filing History |
| 2023-02-14 4:00 pm Sale |
2022-12-31 | 13G | Albireo Pharma, Inc. ALBO |
TANG CAPITAL PARTNERS LP | 411,968 2.000% |
-687,548 (-62.53%) |
Filing History |
| 2023-02-14 4:00 pm Purchase |
2022-12-31 | 13G | ASLAN Pharmaceuticals Limited ASLN |
TANG CAPITAL PARTNERS LP | 670,616 7.800% |
670,616 (New Position) |
Filing History |
| 2023-02-14 4:00 pm Purchase |
2022-12-31 | 13G | BioAtla, Inc. BCAB |
TANG CAPITAL PARTNERS LP | 3,124,076 8.600% |
835,176 (+36.49%) |
Filing History |
| 2023-02-14 4:00 pm Purchase |
2022-12-31 | 13G | bluebird bio, Inc. BLUE |
TANG CAPITAL PARTNERS LP | 231,776 5.600% |
45,724 (+24.58%) |
Filing History |
| 2023-02-14 4:00 pm Purchase |
2022-12-31 | 13G | Tonix Pharmaceuticals Holding Corp. TNXP |
TANG CAPITAL PARTNERS LP | 225 7.400% |
11 (+5.13%) |
Filing History |
| 2023-02-14 4:00 pm Purchase |
2022-12-31 | 13G | Aligos Therapeutics, Inc. ALGS |
TANG CAPITAL PARTNERS LP | 112,656 7.100% |
18,300 (+19.39%) |
Filing History |
| 2023-02-14 4:00 pm Purchase |
2022-12-31 | 13G | Altimmune, Inc. ALT |
TANG CAPITAL PARTNERS LP | 2,700,450 5.500% |
500,450 (+22.75%) |
Filing History |
| 2023-02-14 4:00 pm Sale |
2022-12-31 | 13G | Veru Inc. VERU |
TANG CAPITAL PARTNERS LP | 0 0.000% |
-4,130,339 (Position Closed) |
Filing History |
| 2023-02-13 4:00 pm Purchase |
2023-02-03 | 13G | Magenta Therapeutics, Inc. MGTA |
TANG CAPITAL PARTNERS LP | 5,880,933 9.700% |
5,880,933 (New Position) |
Filing History |
| 2022-12-27 5:06 pm Purchase |
2022-12-16 | 13G | Aligos Therapeutics, Inc. ALGS |
TANG CAPITAL PARTNERS LP | 94,356 5.900% |
94,356 (New Position) |
Filing History |
| 2022-12-27 5:05 pm Purchase |
2022-12-16 | 13G | Tonix Pharmaceuticals Holding Corp. TNXP |
TANG CAPITAL PARTNERS LP | 214 7.400% |
214 (New Position) |
Filing History |
| 2022-12-19 4:00 pm Purchase |
2022-12-08 | 13G | Metacrine, Inc. MTCR |
TANG CAPITAL PARTNERS LP | 3,041,377 7.100% |
3,041,377 (New Position) |
Filing History |
| 2022-11-04 4:00 pm Purchase |
2022-10-25 | 13G | Pyxis Oncology, Inc. PYXS |
TANG CAPITAL PARTNERS LP | 1,981,426 5.600% |
1,981,426 (New Position) |
Filing History |
| 2022-09-26 4:00 pm Purchase |
2022-09-15 | 13G | Albireo Pharma, Inc. ALBO |
TANG CAPITAL PARTNERS LP | 1,099,516 5.600% |
1,099,516 (New Position) |
Filing History |